Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Prasugrel Hydrochloride

FDA-approved product (tablet, oral), marketed as Effient, Prasugrel, Prasugrel Hydrochloride.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Prasugrel Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acute coronary syndrome
  • Hemorrhage
  • Intermediate coronary syndrome
  • Myocardial infarction

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Platelet aggregation inhibitors excl. heparin
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA64.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli54.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae44.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Prasugrel Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Prasugrel Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Dual Antiplatelet Therapy Strategies After Acute Myocardial Infarction Undergoing PCI: Prasugrel vs Ticagrelor & 12 Months vs 1-3 Months

    NCT07507500 · start 2026-09-02

    Registered record
    Registry ID
    NCT07507500
    Conditions
    Myocardial Infarction (MI)
    Interventions
    Prasugrel; Ticagrelor
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-09-02
    Completion
    2030-01
    Enrolment
    8,100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyocardial Infarction (MI)
    InterventionPrasugrel; Ticagrelor
    PhasePhase 4
    Registry statusRecruiting

  • Comparison of Short Versus 12 Months Prasugrel Plus Aspirin in Patients with Acute Coronary Syndromes Treated with Percutaneous Coronary Intervention and Everolimus-eluting Stents

    NCT06718179 · start 2024-11-16

    Registered record
    Registry ID
    NCT06718179
    Conditions
    Acute Coronary Syndrome
    Interventions
    Short duration of aspirin and prasugrel; Conventional duration of aspirin and prasugrel
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-11-16
    Completion
    2030-12
    Enrolment
    3,150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Coronary Syndrome
    InterventionShort duration of aspirin and prasugrel; Conventional duration of aspirin and prasugrel
    PhasePhase 4
    Registry statusRecruiting

  • The Switching Antiplatelet-9 (SWAP-9) Study

    NCT06588595 · start 2024-11-01

    Registered record
    Registry ID
    NCT06588595
    Conditions
    Coronary Arterial Disease (CAD)
    Interventions
    Prasugrel/Ticagrelor monotherapy or aspirin plus clopidogrel; Aspirin plus clopidogrel
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-11-01
    Completion
    2027-02-28
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Arterial Disease (CAD)
    InterventionPrasugrel/Ticagrelor monotherapy or aspirin plus clopidogrel; Aspirin plus clopidogrel
    PhasePhase 4
    Registry statusRecruiting

  • Prospective, Post-registration, Interventional, Randomized, in Parallel Groups, Multicenter Eurasian Clinical Study of DERIVO®/DERIVO® Mini Aneurysm Embolization Device, Europe-Asia

    NCT06400940 · start 2023-08-17

    Registered record
    Registry ID
    NCT06400940
    Conditions
    Intracranial Aneurysm
    Interventions
    ticagrelor (tablets, 180 mg) or prasugrel (tablets, 10 mg).; combination of clopidogrel (tablets, 75 mg) and acetylsalicylic acid (ASA, tablets, 100 mg) or a combination of ticagrelor (tablets, 180 mg) and ASA (tablets, 100 mg).
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2023-08-17
    Completion
    2028-08
    Enrolment
    640

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntracranial Aneurysm
    Interventionticagrelor (tablets, 180 mg) or prasugrel (tablets, 10 mg).; combination of clopidogrel (tablets, 75 mg) and acetylsalicylic acid (ASA, tablets, 100 mg) or a combination of ticagrelor (tablets, 180 mg) and ASA (tablets, 100 mg).
    PhasePhase 4
    Registry statusRecruiting

  • Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS

    NCT05646394 · start 2022-07-01

    Registered record
    Registry ID
    NCT05646394
    Conditions
    Antiphospholipid Syndrome; Arterial Thrombosis
    Interventions
    Dual antiplatelet therapy; Combined antithrombotic therapy; Vitamin K antagonist standard intensity; Vitamin K antagonist high intensity
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2022-07-01
    Completion
    2029-12-31
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAntiphospholipid Syndrome; Arterial Thrombosis
    InterventionDual antiplatelet therapy; Combined antithrombotic therapy; Vitamin K antagonist standard intensity; Vitamin K antagonist high intensity
    PhaseNot recorded
    Registry statusRecruiting

  • Low Dose Prasugrel vs Clopidogrel for Stenting or Flow Diverter for Unruptured Aneurysm

    NCT05359224 · start 2022-06-13

    Registered record
    Registry ID
    NCT05359224
    Conditions
    Intracranial Aneurysm
    Interventions
    Prasugrel group; Clopidogrel group
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2022-06-13
    Completion
    2025-08
    Enrolment
    406

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntracranial Aneurysm
    InterventionPrasugrel group; Clopidogrel group
    PhasePhase 4
    Registry statusUnknown

  • Antiplatelet Therapies in Patients With Depression and Coronary Disease

    NCT05821062 · start 2022-04-14

    Registered record
    Registry ID
    NCT05821062
    Conditions
    Coronary Artery Disease; Depression
    Interventions
    standard Aspirin (ASA) + clopidogrel (CLP) therapy; standard Aspirin (ASA) + Ticagrelor (TCG) or Prasugrel (PSG) therapy; standard ASA therapy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2022-04-14
    Completion
    2024-02
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease; Depression
    Interventionstandard Aspirin (ASA) + clopidogrel (CLP) therapy; standard Aspirin (ASA) + Ticagrelor (TCG) or Prasugrel (PSG) therapy; standard ASA therapy
    PhaseNot recorded
    Registry statusUnknown

  • Clopidogrel Monotherapy in Patients With High Bleeding Risk

    NCT05223335 · start 2022-03-29

    Registered record
    Registry ID
    NCT05223335
    Conditions
    Bleeding Complications
    Interventions
    Clopidogrel; Prasugrel; Tricagrelor
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2022-03-29
    Completion
    2023-03-16
    Enrolment
    98

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBleeding Complications
    InterventionClopidogrel; Prasugrel; Tricagrelor
    PhasePhase 4
    Registry statusCompleted

  • Switching From Ticagrelor to Prasugrel in Patients With Acute Coronary Syndrome

    NCT05183178 · start 2022-02-01

    Registered record
    Registry ID
    NCT05183178
    Conditions
    Acute Coronary Syndrome
    Interventions
    Prasugrel 10 mg p.o; Ticagrelor 90 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2022-02-01
    Completion
    2025-08-31
    Enrolment
    17,095

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Coronary Syndrome
    InterventionPrasugrel 10 mg p.o; Ticagrelor 90 mg
    PhasePhase 4
    Registry statusCompleted

  • Prasugrel in Severe COVID-19 Pneumonia

    NCT04445623 · start 2020-07

    Registered record
    Registry ID
    NCT04445623
    Conditions
    COVID19; Thrombosis
    Interventions
    Prasugrel Hydrochloride 10 MG Oral Tablet; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2020-07
    Completion
    2021-01
    Enrolment
    128

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID19; Thrombosis
    InterventionPrasugrel Hydrochloride 10 MG Oral Tablet; Placebo
    PhasePhase 3
    Registry statusUnknown

  • Study of AggreGuide A-100 (ADP) Assay

    NCT03111420 · start 2017-01-09

    Registered record
    Registry ID
    NCT03111420
    Conditions
    Risk Factor, Cardiovascular; Platelet Dysfunction Due to Drugs
    Interventions
    P2Y12 inhibitor; Platelet function test
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2017-01-09
    Completion
    2018-06
    Enrolment
    280

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRisk Factor, Cardiovascular; Platelet Dysfunction Due to Drugs
    InterventionP2Y12 inhibitor; Platelet function test
    PhaseNot applicable
    Registry statusCompleted

  • Ticagrelor vs. Prasugrel Effects on Infarct Size

    NCT02507323 · start 2016-02

    Registered record
    Registry ID
    NCT02507323
    Conditions
    Cardiovascular Disease
    Interventions
    ticagrelor; prasugrel; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2016-02
    Completion
    2017-11
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Disease
    Interventionticagrelor; prasugrel; Placebo
    PhasePhase 2
    Registry statusWithdrawn

  • Prasugrel vs. Ticagrelor on Myocardial Injury in STEMI

    NCT03435133 · start 2015-11-23

    Registered record
    Registry ID
    NCT03435133
    Conditions
    ST Elevation Myocardial Infarction
    Interventions
    Prasugrel; Ticagrelor
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2015-11-23
    Completion
    2018-12-31
    Enrolment
    61

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionST Elevation Myocardial Infarction
    InterventionPrasugrel; Ticagrelor
    PhaseNot applicable
    Registry statusCompleted

  • Impact of Antiretroviral Treatment on Pharmacokinetics and Pharmacodynamics of Thienopyridines in Healthy Volunteers and HIV Patients

    NCT03054207 · start 2015-06

    Registered record
    Registry ID
    NCT03054207
    Conditions
    Hiv
    Interventions
    Clopidogrel 300Mg Tablet; Prasugrel 60Mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2015-06
    Completion
    2017-04
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHiv
    InterventionClopidogrel 300Mg Tablet; Prasugrel 60Mg
    PhasePhase 1
    Registry statusTerminated

  • Reducing Micro Vascular Dysfunction in Acute Myocardial Infarction by Ticagrelor

    NCT02422888 · start 2015-05

    Registered record
    Registry ID
    NCT02422888
    Conditions
    Myocardial Infarction
    Interventions
    Ticagrelor; Prasugrel
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2015-05
    Completion
    2019-10
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyocardial Infarction
    InterventionTicagrelor; Prasugrel
    PhasePhase 4
    Registry statusUnknown